Together we will beat cancerDonate
Cancer vaccine development has had many challenges. But with recent breakthroughs and new partnerships, could we be closer than ever?
The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours.
Cancer Research UK’s spin-out, GammaDelta Therapeutics, has been given approval to trial its unique T-cell therapy in the US.
In this Science Surgery post Millie asks: ‘Why doesn’t the immune system attack cancer cells?’ The short answer is it does! But sometimes it needs a helping hand from exciting new treatments.
Our new research partnership is exploring common ground between arthritis and cancer, which could bring benefits to patients on both sides.